Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

10-06-2019 | Gout | Highlight | News

European recommendations for the diagnosis of gout issued

EULAR has issued eight updated evidence-based recommendations to guide the diagnosis of gout.

07-06-2019 | Rheumatoid arthritis | Case study | Article

Tofacitinib in a patient with refractory severe rheumatoid arthritis

Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.

10-06-2019 | Psoriatic arthritis | Feature | Article

A closer look at guidelines for the management of PsA

Laura Coates talks to medwireNews about the latest ACR/NPF guidelines for managing psoriatic arthritis, discussing the evidence supporting the recommendations and how they compare with others.

Annual European Congress of Rheumatology coverage

Breaking news and expert interviews from the EULAR 2019 congress, Madrid (June 12–15).

Latest from across the site

17-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Filgotinib beneficial for RA patients with no prior methotrexate exposure

Filgotinib, given in combination with methotrexate, may be a promising treatment option for methotrexate-naïve patients with moderate-to-severe rheumatoid arthritis, indicate findings from the FINCH 3 trial.

17-06-2019 | JAK inhibitors | EULAR 2019 | News

EQUATOR analysis shows patient-level response to filgotinib in PsA

Analysis of the EQUATOR trial has shown that patients treated with the Janus kinase inhibitor filgotinib for active psoriatic arthritis generally achieve a quick response that remains stable over time.

17-06-2019 | Juvenile idiopathic arthritis | EULAR 2019 | News

Further investigation of tocilizumab for JIA-associated uveitis may be warranted

Approximately half of the 21 patients with juvenile idiopathic arthritis-associated uveitis in the APTITUDE trial experienced an improvement in uveitis assessment with 12 weeks of tocilizumab treatment.

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 3 trial

Roy Fleischmann discusses his main take-home messages from the FINCH 3 trial (1:57).

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Expert commentary: The SPIRIT-H2H trial

Laura Coates discusses why the results of the SPIRIT-H2H trial are important for clinical practice (2:41).

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 trial

Roy Fleischmann gives his perspective on the FINCH 1 trial results (1:58)

Latest from us on Twitter

Trending this week

Meet our Editorial Board

New Content Item Meet our Advisory Board

Image Credits